Home Cart Sign in  
Chemical Structure| 88191-84-8 Chemical Structure| 88191-84-8

Structure of MDL-28170
CAS No.: 88191-84-8

Chemical Structure| 88191-84-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MDL28170 is a potent, selective inhibitor of calpain and cathepsin B (Ki values are 10 and 25 nM respectively) that does not inhibit trypsin-like serine proteases. MDL28170 rapidly penetrates the blood-brain barrier following systemic administration and displays neuroprotective effects in vivo.

Synonyms: Calpain Inhibitor III

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MDL-28170

CAS No. :88191-84-8
Formula : C22H26N2O4
M.W : 382.45
SMILES Code : O=C(OCC1=CC=CC=C1)N[C@@H](C(C)C)C(NC(CC2=CC=CC=C2)C=O)=O
Synonyms :
Calpain Inhibitor III
MDL No. :MFCD28137700

Safety of MDL-28170

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Related Pathways of MDL-28170

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Control fibroblasts 100 μM 1-hour pretreatment followed by 8 min hypotonic stress MDL-28170 partially attenuated vimentin cleavage induced by hypotonic stress but did not eliminate it. MG-132 nearly completely inhibited vimentin cleavage. PMC9664965
GAN patient-derived fibroblasts 100 μM 1-hour pretreatment followed by 8 min hypotonic stress MDL-28170 partially attenuated vimentin cleavage induced by hypotonic stress but did not eliminate it. MG-132 (calpain/proteasome inhibitor) nearly completely inhibited vimentin cleavage. PMC9664965
Huh-7-ACE2 cells 2.5 μM 24 hours To validate the antiviral activity of MDL-28170 in human cell lines PMC7603405
Pulmonary artery smooth muscle cells (PASMCs) 10 μM 24 hours MDL-28170 treatment showed protective effects on hypoxia-induced inflammation, fibrosis, and cell proliferation, which may be associated with the downregulation of calpain-1 and p-STAT3 expression in mice and cells. PMC11258379
Leishmania amazonensis promastigotes 15, 20, 25, 30 µM 24, 48, 72, 96 hours To evaluate the effect of MDL-28170 on the growth rate of L. amazonensis. Results showed that MDL-28170 inhibited parasite growth in a dose-dependent manner, with an LD50 of 23.3 µM at 48 hours. At 30 µM, growth inhibition reached 90% after 48 hours. PMC7126437
IPSC-derived pneumocyte-like cells 5 μM 48 hours To evaluate the antiviral activity of MDL-28170 in human primary cell models PMC7603405
Vero E6 cells 5 μM 72 hours To evaluate the inhibitory effect of MDL-28170 on SARS-CoV-2 replication PMC7603405
HEK293 cells 20 μM MDL-28170, as a reversible calpain inhibitor, preferentially affected rCAPN1 over rCAPN14 activity. PMC4855700

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Cancer-induced bone pain model Intraperitoneal injection 1 mg/kg Daily administration until postoperative day 14 To evaluate the effect of MDL-28170 on mechanical withdrawal thresholds in a rat cancer-induced bone pain model. Results showed that MDL-28170 significantly increased the mechanical withdrawal thresholds of both surgical and nonsurgical hind paws and reduced TRAP-positive cell counts. PMC4832953
Pigs Right ventricular pressure overload model Infusion into the right coronary artery 10 µM Continued for 4 hours MDL-28170 attenuated the severity of right ventricular contractile dysfunction and preserved talin abundance in the RV free wall. PMC3488694
Mice Wild-type (WT), junctin-knockout (JKO), and triadin-knockout (TKO) mice Perfusion buffer 10 μM Administered 5 min prior to ischemia and continued for 5 min after reperfusion MDL-28170 significantly improved the recovery of contractile function post-I/R in WT, JKO, and TKO hearts, reduced myocardial infarct size and cTnI degradation PMC3331615
Pigs Right ventricular pressure overload model Infusion into the right coronary artery 10 μM per liter Continued for 4 hours MDL-28170 attenuated the severity of right ventricular contractile dysfunction and preserved talin abundance in the RV free wall. PMC3488694
Pigs Acute right ventricular pressure overload model Intracoronary infusion 10 μM per liter Continuous infusion for 90 minutes MDL-28170 significantly attenuated right ventricular contractile dysfunction caused by acute right ventricular pressure overload PMC2268883
Mice Endotoxin-induced diaphragmatic dysfunction model Intraperitoneal injection 12 mg/kg Single dose, evaluated after 24 hours To evaluate the effect of calpain inhibitor III on endotoxin-induced diaphragmatic dysfunction. Results showed that calpain inhibitor III prevented endotoxin-induced increases in calpain activity, reduced talin degradation, and attenuated diaphragm force reduction. PMC2809221
C57BL/6 mice Postoperative cognitive dysfunction (POCD) model Intraperitoneal injection 20 mg/kg Once before surgery and once daily for 5 consecutive days after surgery MDL-28170 treatment reversed anesthesia and surgery-induced truncation of TrkB-FL, BDNF/TrkB signaling dysregulation, dendritic spine loss, and cell apoptosis, and improved cognitive impairments in aging mice. PMC6966800
Mice Podocyte-specific Gak knockout mice Intraperitoneal injection 20 mg/kg/day Daily starting from 2 weeks of age Inhibit calpain-1/-2 activities, reduce proteinuria and glomerulosclerosis PMC7710277
Mice Gak knockout mice Intraperitoneal injection 20 mg/kg/day Once daily, starting from 2 weeks of age Inhibited calpain-1 and -2 activities, mitigated proteinuria and glomerulosclerosis, and significantly increased survival PMC7710277
Sprague Dawley rats Epilepsy model Intraperitoneal injection 50 mg/kg Low-dose treatment: two acute injections at 1 and 5 h after SE onset with a final dose the following morning; High-dose treatment: four acute doses at 1, 3, 5 and 9 h after SE onset with a final dose the following morning. To evaluate the effects of MDL-28170 on seizure burden. Results showed that low-dose treatment significantly reduced seizure frequency and was correlated with a reduction in tissue inflammation and cell sprouting. PMC5640433
Mice Mth1/Ogg1-DKO mice Intraperitoneal injection 50 mg/kg/day Once daily for 7 days MDL28170 significantly improved 3-NP-induced motor impairments and suppressed MSN loss and microgliosis. PMC3533558
Sprague-Dawley (SD) rats Traumatic brain injury (TBI) model Intracranial injection 50 mM Single dose, assessed after 30 minutes MDL28170 improved the post-TBI microenvironment by inhibiting inflammation and apoptosis, enhanced the survival of transplanted BMSCs, and significantly improved neurological function. PMC6420775

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.61mL

0.52mL

0.26mL

13.07mL

2.61mL

1.31mL

26.15mL

5.23mL

2.61mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories